Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results [Yahoo! Finance]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Yahoo! Finance
company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "Our eosinophilic esophagitis ("EoE") clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study continues to suggest that EP-104GI could represent a significant improvement over currently approved therapies for this debilitating condition," said Dr. James Helliwell , CEO of Eupraxia. "In addition, during the second quarter, we presented data at two medical meetings highlighting the potential of our candidate for the treatment of knee osteoarthritis ("OA"), EP-104IAR, which also holds the potential to advance the current standard of care in OA." Dr. Helliwell continued, "Looking ahead, we anticipate reporting new data from the fourth cohort of the RESOLVE study in
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal DiseasesPR Newswire
- Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPR Newswire
- Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR Newswire
- Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsPR Newswire
EPRX
Sec Filings
- 9/19/24 - Form 6-K
- 9/11/24 - Form 6-K
- 9/4/24 - Form 6-K
- EPRX's page on the SEC website